Comprehensive characterization of MET exon 14 skipping mutations in non-small cell lung cancer

被引：0
|
作者：
Wu, Xue
Zhang, Yaru
Pang, Jiaohui
Lin, Li
Yin, Jiani C.
Tang, Haimeng
Shao, Yang
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 07期
关键词：
D O I：
10.1158/1538-7445.AM2023-940
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
940
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Clinical outcomes in advanced Non-Small Cell Lung Cancer (NSCLC) with MET exon 14 skipping mutation
    Smith, Miles
    Carter, Mat
    Woodhouse, Laura
    Adderley, Helen
    Morrissey, George
    Brown, Kate
    Nicola, Pantelis
    Weaver, Jamie
    Califano, Raffaele
    Summers, Yvonne
    Cove-Smith, Laura
    Hughes, Sarah
    Taylor, Paul
    Blackhall, Fiona
    Lindsay, Colin R.
    LUNG CANCER, 2024, 190
  • [42] Tepotinib: Management of Adverse Events in Patients With MET Exon 14 Skipping Non-Small Cell Lung Cancer
    Ahn, Linda
    Alexander, Terri
    Vlassak, Soetkin
    Berghoff, Karin
    Lemmens, Liesbeth
    CLINICAL JOURNAL OF ONCOLOGY NURSING, 2022, 26 (05) : 543 - 551
  • [43] Immunotherapy for stage IV non-small cell lung cancer patients with MET exon 14 skipping mutation
    Kuon, J.
    Blasi, M.
    Shah, R.
    Christopoulos, P.
    Stenzinger, A.
    Kazdal, D.
    Herth, F. J.
    Heussel, C. P.
    Thomas, M.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 172 - 172
  • [44] Genomic and Immune Landscape Comparison of MET Exon 14 Skipping and MET-Amplified Non-small Cell Lung Cancer
    Minne, Rachel L.
    Luo, Natalie Y.
    Traynor, Anne M.
    Huang, Minxuan
    Detullio, Luisina
    Godden, Jen
    Stoppler, Melissa
    Kimple, Randall J.
    Baschnagel, Andrew M.
    CLINICAL LUNG CANCER, 2024, 25 (06)
  • [45] MET Exon 14 Skipping Mutations Essential Considerations for Current Management of Non-Small-Cell Lung Cancer
    Davies, Kurtis D.
    Ritterhouse, Lauren L.
    Snow, Anthony N.
    Sidiropoulos, Nikoletta
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2022, 24 (08): : 841 - 843
  • [46] MOMENT REGISTRY (MET NON SMALL CELL CANCER REGISTRY) FOR ADVANCED NON-SMALL CELL LUNG CANCER (ANSCLC) HARBORING MET EXON 14 (METEX14) SKIPPING
    Thomas, M.
    Christopoulos, P.
    Iams, W. T.
    Mazieres, J.
    Cortot, A. B.
    Peled, N.
    Minuti, G.
    Smit, E. F.
    Ahrens, S.
    Berghoff, K.
    Eggleton, S. P.
    Fries, F.
    Liu, P.
    Mahmoudpour, S. H.
    Menzel, C.
    O'Brate, A.
    Stroh, C.
    Oksen, D.
    VALUE IN HEALTH, 2023, 26 (12) : S527 - S527
  • [47] Oncogenic KRAS mediates resistance to MET targeted therapy in non-small cell lung cancer (NSCLC) with MET mutations that induce exon14 skipping
    Suzawa, Ken
    Offin, Michael D.
    Kurzatkowski, Christopher
    Liu, Daniel
    Vojnic, Morana
    Smith, Roger S.
    Mattar, Marissa
    Khodos, Inna
    de Stanchina, Elisa
    Sabari, Joshua K.
    Lockwood, William W.
    Drilon, Alexander E.
    Ladanyi, Marc
    Somwar, Romel
    CANCER RESEARCH, 2018, 78 (13)
  • [48] Post-marketing surveillance of tepotinib for non-small cell lung cancer with MET exon 14 skipping mutations e final report
    Kato, Terufumi
    Ogura, Tatsuya
    Sato, Masashi
    Kojima, Risa
    Song, Bingbing
    Horii, Eisuke
    Nakagawa, Kazuhiko
    ANNALS OF ONCOLOGY, 2023, 34 : S1420 - S1421
  • [49] Prevalence of MET exon 14-mutations or MET amplification in non-small cell lung cancer in Swiss patients
    Prince, S. Savic
    Bihl, M.
    Eppenberger-Castori, S.
    Matter, M. S.
    Zellweger, N.
    Rothschild, S. I.
    Bubendorf, L.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S700 - S700
  • [50] Health Utility Analysis of Tepotinib in Patients With Non-Small Cell Lung Cancer Harboring MET Exon 14 Skipping
    Yang, Mo
    Vioix, Helene
    Hook, Emma S.
    Hatswell, Anthony J.
    Batteson, Rachael L.
    Gaumond, Bruce R.
    O'Brate, Aurora
    Popat, Sanjay
    Paik, Paul K.
    VALUE IN HEALTH, 2023, 26 (08) : 1155 - 1163
12345